Table 3.

Best overall response as per local investigator assessment per RANO criteria, by treatment

	Buparlisib (80 mg)+carboplatin (n=3)	Buparlisib (100 mg)+carboplatin (n=14)	Buparlisib (60 mg)+lomustine (n=18)
Patients with measurable enhancing T1 lesion at baseline, n (%)	3 (100)	14 (100)	16 (88.9)
Patients with non-measurable, non-enhancing T2/FLAIR lesion at baseline, n (%)	2 (66.7)	3 (21.4)	6 (33.3)
Best overall response, n (%)
Complete response (CR)	0	0	0
Partial response (PR)	1 (33.3)	0	0
Stable disease (SD)	0	3 (21.4)	2 (11.1)
Progressive disease (PD)	2 (66.7)	11 (78.6)	14 (77.8)
Unknown	0	0	2 (11.1)
Overall response rate (ORR)*, n (%) (95% CI)	1 (33.3) (0.8 to 90.6)	0 (0.0 to 23.2)	0 (0.0 to 18.5)
Disease control rate (DCR)†, n (%) (95% CI)	1 (33.3) (0.8 to 90.6)	3 (21.4) (4.7 to 50.8)	2 (11.1) (1.4 to 34.7)

*ORR includes CR+PR

†DCR includes CR+PR+SD.

FLAIR, fluid attenuated inversion recovery; RANO, Response Assessment in Neuro-Oncology.